Voyager Therapeutics (VYGR) CEO auto-sells 14,197 shares to cover taxes

Rhea-AI Filing Summary

Voyager Therapeutics, Inc. director and President & CEO Alfred Sandrock reported an open-market sale of common stock tied to tax withholding. He sold 14,197 shares of common stock at a weighted average price of $3.79 per share in transactions on February 24, 2026.

The sale was executed under a durable automatic sale instruction adopted on May 12, 2025 to satisfy tax withholding obligations arising from the vesting of restricted stock units on February 21, 2026, and is described as not a discretionary trade. Following these transactions, Sandrock directly holds 484,060 shares of Voyager Therapeutics common stock.

Insider Trade Summary

Net Seller: 14,197 shares ($53,807)

Net Sell 1 txn

Insider Sandrock Alfred

Role President and CEO

Sold 14,197 shs ($54K)

Type	Security	Shares	Price	Value
Sale	Common Stock	14,197	$3.79	$54K

Holdings After Transaction: Common Stock — 484,060 shares (Direct)

Footnotes (1)

1. Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 21, 2026. The sales do not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sandrock Alfred

(Last) (First) (Middle)

C/O VOYAGER THERAPEUTICS, INC.

75 HAYDEN AVENUE

(Street)

LEXINGTON MA 02421

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Voyager Therapeutics, Inc. [ VYGR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		S(1)		14,197(1)	D	$3.79(2)	484,060	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of common stock of Voyager Therapeutics, Inc. (the "Corporation") sold, pursuant to a durable automatic sale instruction adopted by the reporting person on May 12, 2025, effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on February 21, 2026. The sales do not represent a discretionary trade by the reporting person.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.61 to $3.86, inclusive. The reporting person undertakes to provide to the Corporation, any security holder of the Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

	/s/ Gregory L. Shiferman, as Attorney-in-Fact for Alfred Sandrock	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Voyager Therapeutics (VYGR) CEO Alfred Sandrock report in this Form 4?

Alfred Sandrock reported selling 14,197 shares of Voyager Therapeutics common stock. The transactions were open-market sales executed under an automatic instruction to cover tax withholding from recently vested restricted stock units.

At what price were the VYGR shares sold in Alfred Sandrock’s Form 4 filing?

The filing reports a weighted average price of $3.79 per share. Footnotes explain the shares were sold in multiple trades at prices ranging from $3.61 to $3.86, and detailed breakdowns are available upon request.

Why did Voyager Therapeutics CEO Alfred Sandrock sell shares according to this Form 4?

The sale was made to cover tax withholding obligations tied to restricted stock units vesting on February 21, 2026. It followed a durable automatic sale instruction adopted on May 12, 2025 and is characterized as non-discretionary.

How many Voyager Therapeutics shares does Alfred Sandrock hold after this reported sale?

After the reported transactions, Alfred Sandrock directly owns 484,060 shares of Voyager Therapeutics common stock. This post-transaction holding is disclosed in the Form 4 as the total number of shares beneficially owned following the sale.

Was the VYGR Form 4 sale by Alfred Sandrock an open-market transaction?

Yes, the Form 4 describes the transaction as an open-market sale of common stock. It was executed under a pre-established automatic sale instruction specifically to satisfy tax withholding associated with the vesting of restricted stock units.

Do the Form 4 footnotes indicate that Alfred Sandrock’s VYGR sale was discretionary?

No, the footnotes state the sales do not represent a discretionary trade. They clarify the shares were sold pursuant to a durable automatic sale instruction used to effect a sell-to-cover election for tax withholding obligations.